Dexmethylphenidate

For adults diagnosed with ADHD, the dosage of dexmethylphenidate must be individualized based on therapeutic needs and patient response.

• Immediate-Release (IR): The typical starting dose for adults new to methylphenidate is 5 mg taken twice daily (10 mg total per day). Your healthcare provider may increase the dose in increments of 2.5 mg to 5 mg at weekly intervals. The maximum recommended daily dose is 20 mg (10 mg twice daily).
• Extended-Release (XR): For adults not currently taking methylphenidate, the recommended starting dose is 10 mg once daily. The dose may be adjusted in 10 mg increments weekly. The maximum recommended dose for Focalin XR in adults is 40 mg per day.
• Switching from Methylphenidate: If a patient is switching from racemic methylphenidate (Ritalin) to dexmethylphenidate, the starting dose should be half the dose of the racemic mixture.

Dexmethylphenidate is FDA-approved for use in children aged 6 years and older. It is not recommended for children under the age of 6, as safety and efficacy have not been established in this age group.

• Immediate-Release (IR): The starting dose for pediatric patients is 2.5 mg twice daily. The dosage can be titrated upward in increments of 2.5 mg weekly. The maximum dose is 20 mg per day (10 mg twice daily).
• Extended-Release (XR): The starting dose for pediatric patients is 5 mg once daily. Dosage may be increased by 5 mg weekly. The maximum dose for children is 30 mg per day, though some clinical scenarios may warrant up to 40 mg under strict supervision.

Renal Impairment

There are no specific dosage adjustment guidelines provided by the manufacturer for patients with renal impairment. Since dexmethylphenidate is primarily metabolized into an inactive metabolite and excreted by the kidneys, significant accumulation of the active drug is unlikely. However, caution is advised in patients with severe renal disease.

Hepatic Impairment

Specific guidelines for hepatic impairment are not available. However, because the primary metabolic pathway involves de-esterification (not CYP450 metabolism), hepatic dysfunction may not significantly alter the clearance of the drug. Nevertheless, patients with liver disease should be monitored closely.

Elderly Patients

Clinical studies of dexmethylphenidate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.

• Timing: Immediate-release tablets are usually taken twice daily, at least 4 hours apart (e.g., at breakfast and lunch). Avoid taking doses late in the day to prevent insomnia (difficulty sleeping). Extended-release capsules should be taken once daily in the morning.
• Food: Dexmethylphenidate can be taken with or without food. However, taking it with food may help reduce stomach upset. For the XR version, a high-fat meal can delay the onset of the second peak of the medication.
• Administration (XR Capsules): Extended-release capsules should ideally be swallowed whole with water or other liquids. For patients who have difficulty swallowing capsules, the XR capsule may be opened and the entire contents sprinkled onto a small amount (one tablespoon) of applesauce. The mixture should be consumed immediately without chewing the beads. Do not store the mixture for future use.
• Storage: Store at room temperature (20°C to 25°C or 68°F to 77°F) in a tight, light-resistant container. Keep out of reach of children to prevent accidental ingestion.

If a dose is missed, it should be taken as soon as remembered, unless it is late in the afternoon or evening. If it is near the time for the next day's dose, skip the missed dose and resume the regular schedule. Do not 'double up' or take two doses at once to make up for a missed one, as this increases the risk of side effects.

Signs of a dexmethylphenidate overdose may include vomiting, agitation, tremors, muscle twitching, seizures, confusion, hallucinations, sweating, flushing, headache, high fever, fast or irregular heartbeat, high blood pressure, and dilated pupils. In the event of a suspected overdose, contact a poison control center or seek emergency medical attention immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as sudden discontinuation can lead to withdrawal symptoms.

Common side effects are those that occur in more than 10% of patients. These are often dose-dependent and may diminish over time as the body adjusts to the medication.

• Abdominal Pain: Often described as a 'stomach ache' or cramping, this is particularly common in children. Taking the medication with food can mitigate this effect.
• Decreased Appetite: Stimulants frequently suppress the desire to eat, which can lead to weight loss. This is usually most pronounced during the middle of the day.
• Insomnia: Difficulty falling asleep or staying asleep is common, especially if the medication is taken too late in the day.
• Dry Mouth (Xerostomia): A feeling of dryness in the mouth, which can sometimes lead to increased thirst or dental issues if persistent.
• Nausea: A feeling of sickness in the stomach, sometimes accompanied by dizziness.

• Tachycardia: An abnormally rapid heart rate. Patients may feel their heart 'racing' or 'pounding' in their chest.
• Anxiety and Nervousness: Some patients may feel 'jittery' or experience increased feelings of worry.
• Dizziness: A sensation of spinning or lightheadedness, particularly when standing up quickly.
• Irritability: Increased moodiness or 'rebound' irritability as the medication wears off in the evening.
• Weight Loss: Due to prolonged appetite suppression, especially in pediatric populations.

• Blurred Vision: Temporary changes in visual acuity or difficulty focusing.
• Tics: The development or worsening of motor or vocal tics (repetitive, involuntary movements or sounds).
• Hypersensitivity Reactions: Including skin rash, urticaria (hives), or fever.
• Alopecia: Temporary thinning of hair or hair loss has been reported in rare instances.

> Warning: Stop taking Dexmethylphenidate and call your doctor immediately if you experience any of the following serious symptoms.

• Cardiovascular Events: Chest pain, shortness of breath, or fainting. Stimulants can increase the risk of sudden death in patients with pre-existing heart defects or serious heart problems.
• Psychotic or Manic Symptoms: Hearing voices, believing things that are not true (delusions), or becoming unusually suspicious (paranoia) in patients without a prior history of psychotic illness.
• Priapism: A painful and prolonged erection lasting more than 4 hours. This is a medical emergency and requires immediate intervention to prevent permanent tissue damage.
• Circulation Problems (Peripheral Vasculopathy): Fingers or toes that feel numb, cold, or painful, or change color from pale to blue to red (Raynaud’s phenomenon).
• Seizures: Especially in patients with a prior history of epilepsy.

• Growth Suppression: Data suggest that long-term use of stimulants in children may cause a temporary slowing in growth rate (both height and weight). Most children eventually reach their expected adult height, but healthcare providers monitor growth charts closely.
• Tolerance and Dependence: Over time, the body may become accustomed to the drug, requiring higher doses to achieve the same effect. Chronic abuse can lead to significant psychological dependence and social dysfunction.
• Cardiac Changes: Long-term elevation in blood pressure and heart rate may have cumulative effects on cardiovascular health, necessitating regular monitoring.

Dexmethylphenidate carries an FDA Black Box Warning regarding its potential for Abuse and Dependence.

Summary of Warning: CNS stimulants, including dexmethylphenidate, have a high potential for abuse and dependence. Healthcare providers should assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy. Maintaining careful prescription records and educating patients and families on the proper storage and disposal of the medication is essential to prevent diversion (sharing or selling the drug).

Report any unusual symptoms or persistent side effects to your healthcare provider immediately. They may adjust your dose or suggest a different treatment plan.

Dexmethylphenidate is a powerful CNS stimulant that requires careful medical supervision. Before starting treatment, patients must undergo a comprehensive medical history review, specifically focusing on cardiovascular health and psychiatric history. It is essential to understand that this medication is a Schedule II controlled substance, meaning it has a high potential for misuse and must be stored securely to prevent theft or unauthorized use.

Abuse, Misuse, and Addiction: Dexmethylphenidate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants can result in overdose and death. Before prescribing, healthcare providers must assess each patient's risk for abuse. Throughout treatment, patients should be monitored for signs of misuse, such as taking more than the prescribed dose or using the drug for non-medical reasons.

Risks of Sudden Death: Misuse of CNS stimulants may cause sudden death and serious cardiovascular adverse events.

• Cardiovascular Risks: Stimulant medications cause a modest increase in average blood pressure (about 2-4 mmHg) and heart rate (about 3-6 bpm). While these increases may be negligible for most, they can be dangerous for individuals with pre-existing hypertension, heart failure, or recent myocardial infarction (heart attack). Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities.
• Psychiatric Risks: Dexmethylphenidate may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic condition. It may also induce mixed/manic episodes in patients with bipolar disorder. Patients should be screened for bipolar disorder before starting stimulants.
• Seizures: There is some clinical evidence that stimulants may lower the convulsive threshold in patients with a prior history of seizures. If seizures occur, the drug should be discontinued.
• Visual Disturbance: Difficulties with accommodation and blurring of vision have been reported with stimulant use. Long-term use may be associated with increased intraocular pressure.
• Growth Monitoring: Because stimulants can suppress appetite and potentially slow growth in children, height and weight should be monitored regularly. 'Drug holidays' (periods without medication, such as during summer break) may be recommended by some physicians to allow for catch-up growth.

Patients on long-term dexmethylphenidate therapy require regular follow-up appointments. Monitoring typically includes:

• Blood Pressure and Heart Rate: Checked at every visit to ensure they remain within safe limits.
• Growth Parameters: Height and weight in pediatric patients, plotted on standardized growth charts.
• Psychiatric Status: Monitoring for the emergence of anxiety, aggression, or suicidal ideation.
• CBC and Differential: Periodic blood counts may be advised during prolonged therapy, although serious hematologic effects are rare.

Dexmethylphenidate may cause dizziness, blurred vision, or other CNS effects that can impair physical or mental abilities. Patients should be cautious when driving a car or operating heavy machinery until they are certain the medication does not adversely affect their performance.

Alcohol should be avoided while taking dexmethylphenidate. Alcohol can exacerbate the side effects of stimulants, such as increased heart rate and blood pressure. Furthermore, in the case of extended-release (XR) formulations, alcohol can cause 'dose dumping,' where the entire day's dose is released into the bloodstream at once, significantly increasing the risk of toxicity.

Do not stop taking dexmethylphenidate abruptly without consulting your doctor. Sudden discontinuation after prolonged use can lead to a 'crash' or withdrawal syndrome, characterized by extreme fatigue, depression, and changes in sleep patterns. A gradual tapering of the dose is usually recommended to minimize these effects.

> Important: Discuss all your medical conditions, especially any history of heart problems or mental health issues, with your healthcare provider before starting Dexmethylphenidate.

• Monoamine Oxidase Inhibitors (MAOIs): Dexmethylphenidate must not be used concurrently with MAOIs (such as phenelzine, selegiline, or tranylcypromine) or within 14 days of discontinuing an MAOI. This combination can trigger a hypertensive crisis—a sudden, life-threatening spike in blood pressure—due to the synergistic increase in norepinephrine levels.

• Antihypertensive Agents: Dexmethylphenidate may decrease the effectiveness of medications used to treat high blood pressure (e.g., ACE inhibitors, beta-blockers, diuretics). Because stimulants naturally raise blood pressure, the dose of antihypertensive medication may need adjustment.
• Halogenated Anesthetics: There is a risk of sudden blood pressure increase during surgery if dexmethylphenidate is used with certain inhaled anesthetics (like halothane or isoflurane). It is often recommended to withhold the stimulant dose on the day of surgery.
• Coumarin Anticoagulants: Stimulants may inhibit the metabolism of coumarin anticoagulants (like warfarin), potentially increasing their blood levels and the risk of bleeding. Prothrombin time (INR) should be monitored closely.

• Anticonvulsants: Dexmethylphenidate may increase the plasma levels of certain anti-seizure medications, such as phenobarbital, phenytoin, and primidone. Monitoring for toxicity of these agents is recommended.
• Tricyclic Antidepressants (TCAs): Stimulants can inhibit the metabolism of TCAs (like amitriptyline or imipramine), leading to increased TCA concentrations and potential cardiac side effects.
• Selective Serotonin Reuptake Inhibitors (SSRIs): While often used together under supervision, the combination can occasionally lead to increased side effects or, in rare cases, serotonin syndrome.

• High-Fat Meals: As noted in the pharmacokinetics section, a high-fat meal can delay the absorption of the second dose within the XR capsule. This might result in the medication lasting longer into the evening, potentially increasing the risk of insomnia.
• Caffeine: Consuming large amounts of caffeine (coffee, tea, energy drinks) while taking dexmethylphenidate can lead to additive stimulant effects, resulting in excessive jitteriness, palpitations, and anxiety.
• Acidic Foods/Juices: Very acidic foods or juices (like orange or grapefruit juice) do not have the same significant impact on dexmethylphenidate as they do on amphetamine-based stimulants, but they can still slightly alter absorption in some individuals.

• St. John's Wort: May increase the risk of serotonin-related side effects when combined with stimulants.
• Ginkgo Biloba: Some evidence suggests Ginkgo may have mild antiplatelet effects and could theoretically interact with the cardiovascular effects of stimulants.
• Melatonin: Often used by patients to combat stimulant-induced insomnia. While generally considered safe, it should be discussed with a doctor to ensure proper timing and dosage.

Dexmethylphenidate is not known to significantly interfere with most common laboratory tests. However, it may cause a false-positive result for amphetamines on some rapid urine drug screens. If a drug test is required (e.g., for employment), it is important to disclose the prescription for dexmethylphenidate to the testing facility.

For each major interaction, the primary management strategy is close clinical monitoring of the patient's vital signs and therapeutic response. Dose adjustments of either the stimulant or the interacting medication may be necessary.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to prevent dangerous drug interactions.

There are several conditions where the risks of using dexmethylphenidate clearly outweigh any potential benefits. In these cases, the medication must not be used.

• Hypersensitivity: Patients with a known allergy to dexmethylphenidate, methylphenidate, or any of the inactive ingredients (such as lactose or starch) in the formulation. Reactions can range from mild rashes to life-threatening anaphylaxis.
• Glaucoma: Because dexmethylphenidate can cause pupillary dilation (mydriasis), it may increase intraocular pressure and worsen narrow-angle glaucoma.
• MAOI Use: As previously mentioned, use within 14 days of a Monoamine Oxidase Inhibitor is strictly prohibited due to the risk of hypertensive crisis.
• Tics and Tourette’s Syndrome: Dexmethylphenidate is contraindicated in patients with motor tics or a family history/diagnosis of Tourette’s syndrome, as stimulants can trigger or exacerbate these involuntary movements.
• Severe Anxiety or Agitation: The drug's stimulant properties can significantly worsen pre-existing states of severe agitation, tension, or anxiety.

These are conditions that require a careful risk-benefit analysis and intense monitoring if the drug is prescribed.

• Structural Cardiac Abnormalities: Including cardiomyopathy or serious heart rhythm disturbances. The risk of sudden death is higher in these populations.
• Bipolar Disorder: Stimulants can induce a manic or mixed episode. A thorough psychiatric screening for bipolar risk factors is essential.
• Seizure Disorders: Use with caution, as the drug may lower the threshold for having a seizure.
• Hypertension: Patients with even mild high blood pressure must be monitored closely, as the drug can further elevate these levels.

Patients who have had a negative reaction to racemic methylphenidate (Ritalin, Concerta) are highly likely to have a similar reaction to dexmethylphenidate. While dexmethylphenidate is only one half of the racemic mixture, the pharmacological profile is nearly identical in terms of allergenicity and side effect profile.

> Important: Your healthcare provider will evaluate your complete medical history, including any family history of sudden death or mental illness, before prescribing Dexmethylphenidate.

Dexmethylphenidate is classified as Pregnancy Category C under the older FDA system. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown some evidence of teratogenicity (birth defects) and fetal toxicity at very high doses.

• Clinical Considerations: Dexmethylphenidate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
• Neonatal Risks: Infants born to mothers dependent on stimulants may experience withdrawal symptoms and exhibit increased risk for low birth weight or premature delivery.
• Registry: Healthcare providers are encouraged to register pregnant patients taking ADHD medications in the National Pregnancy Registry for ADHD Medications to help collect data on safety.

Limited data indicate that dexmethylphenidate is excreted into human breast milk. The 'milk-to-plasma ratio' is relatively low, meaning only small amounts reach the infant. However, the long-term neurodevelopmental effects of exposure to small amounts of stimulants via breast milk are unknown.

• Recommendation: Monitor breastfed infants for signs of increased irritability, poor sleeping patterns, or reduced weight gain. A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Dexmethylphenidate is approved for children 6 years and older.

• Growth: As noted, growth must be monitored. If a child is not growing or gaining weight as expected, the doctor may interrupt treatment.
• Safety: The safety and effectiveness in children under 6 have not been established. Use in this very young population is considered off-label and carries higher risks of behavioral side effects.

There is very little data regarding the use of dexmethylphenidate in patients over 65.

• Risks: Elderly patients are more likely to have pre-existing cardiovascular conditions (hypertension, heart disease) and reduced renal or hepatic function.
• Polypharmacy: The risk of drug interactions is much higher in the elderly due to the increased likelihood of taking multiple medications for other chronic conditions.

In patients with kidney disease, the primary concern is the accumulation of metabolites. While ritalinic acid is inactive, its clearance is delayed in renal failure. However, no specific dose adjustments are currently mandated for dexmethylphenidate in renal impairment. Dialysis is not an effective treatment for overdose because the drug has a large volume of distribution.

Since the liver is not the primary site of active drug metabolism (de-esterification occurs in various tissues), mild to moderate hepatic impairment may not significantly alter the drug's levels. However, patients with severe liver cirrhosis should be treated with extreme caution.

> Important: Special populations require individualized medical assessment and frequent monitoring to ensure safety and efficacy.

Dexmethylphenidate hydrochloride is a central nervous system (CNS) stimulant. It is the d-threo-enantiomer of racemic methylphenidate. It acts primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI). It achieves its effect by binding to the dopamine transporter (DAT) and the norepinephrine transporter (NET) on the presynaptic membrane of neurons. This binding prevents the reabsorption of these neurotransmitters from the synaptic cleft back into the neuron. Consequently, there is an increase in the extracellular levels of dopamine and norepinephrine, which enhances dopaminergic and noradrenergic neurotransmission in the brain, particularly in the prefrontal cortex and striatum.

The pharmacodynamic effects of dexmethylphenidate include increased alertness, improved attention span, and decreased impulsivity. It also has peripheral effects, such as increasing heart rate and blood pressure, and acting as a mild bronchodilator. Tolerance to the behavioral effects can develop over months or years of use, though the mechanism for this tolerance is complex and may involve down-regulation of receptors.

| Parameter | Value |

|---|---|

| Bioavailability | ~22-25% (Extensive first-pass metabolism) |

| Protein Binding | 12% to 15% |

| Half-life | 2 to 3 hours |

| Tmax (IR) | 1 to 1.5 hours |

| Tmax (XR) | 1.5 hours and 6.5 hours (Bimodal) |

| Metabolism | De-esterification via CES1A1 to d-ritalinic acid |

| Excretion | Renal 90%, Fecal 1-3% |

• Molecular Formula: C14H19NO2·HCl
• Molecular Weight: 269.77 g/mol
• Solubility: Freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform.
• Structure: It is a white to off-white powder. Chemically, it is (2R,2'R)-(+)-threo-methyl phenyl-2-piperidineacetate hydrochloride.

Dexmethylphenidate is classified as a CNS stimulant of the phenethylamine and piperidine classes. It is pharmacologically related to other stimulants like amphetamines, although its mechanism (reuptake inhibition) differs slightly from amphetamines (which also promote neurotransmitter release).